Skip to content
Learn More

Resources

iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs

July 8, 2021

BRYAN, Texas, July 08, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, has taken another major step towards leveraging the speed and throughput of its proprietary, plant-based FastPharming Protein Expression System® by announcing today it is adding three anti-cancer targets to its pipeline of therapeutic candidates. …

Read More

iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program

May 6, 2021

BRYAN, Texas, May 06, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today provided an update on its IBIO-201 program and reported on its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201, the Company’s vaccine candidate …

Read More

iBio Appoints Robert M. Lutz as Chief Financial & Business Officer

February 16, 2021

BRYAN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Robert M. Lutz as its Chief Financial & Business Officer (“CFBO”), effective March 4, 2021. “I am pleased to welcome Rob to iBio where we expect he …

Read More

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

December 28, 2020

BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (“CSO”), effective January 18, 2020. “We are thrilled to have Dr. Brenner join our team,” said Tom …

Read More

iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

December 1, 2020

BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development and manufacturing organization (“CDMO”), today announced that it has entered into its first Statement of Work (“SoW”) under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System.

Read More
Top